Table 1.

Clinical characteristics, tumor mutation analysis, and EGFR copy number analysis in metastatic colorectal cancer patients treated by cetuximab

SexAge (y)Previous chemotherapy regimens for metastastic diseaseAnti-EGFR treatmentTumor responseKRAS mutationPIK3CA mutationEGFR copy number *
Best responseDuration (wk)
M77FOLFIRICetuximab and irinotecanCR58.1WTWT20
M61NACetuximab and FOLFIRIPR34.1WTWT11
M76NACetuximab and FOLFIRIPR33.9WTWT2.6
M67NACetuximab and FOLFIRIPR20.9WTWT3.7
M71LV5FU2, FOLFOX, capecitabine and mitomycin, capecitabine and irinotecan, irinotecanCetuximab and irinotecanPR46.0WTWT3
F44LV5FU2 IV and oxaliplatin IAH, FOLFOX IV and Adriamycin IAH, FOLFIRI, irinotecanCetuximab and irinotecanPR62.9WTWT3
M72LV5FU2, LV5FU2 IV and oxaliplatin IAH, FOLFIRI, capecitabine and irinotecanCetuximab and irinotecanPR44.0WTWT2.1
M48LV5FU2, FOLFOX, raltitrexed and oxaliplatin, FOLFIRI, phase I trial, capecitabin and mitomycinCetuximab and irinotecanPR17.1WTWT11
F55FOLFIRI, FOLFOX, irinotecan,cetuximabPR23.7WTWT3.4
F64FOLFOX, FOLFIRICetuximab and irinotecanPR17.1WTWT2.5
M62LV5FU2 IV and oxaliplatin IAH, FOLFOX, FOLFIRICetuximab and irinotecanPR32.0WTWT2.8
M50FOLFIRI, FOLFIRI IV and oxaliplatin IAH, irinotecanCetuximab and irinotecanSD14.7WTWT2.9
F73LV5FU2, FOLFIRI, FOLFOXCetuximab and irinotecanSD19.3G12DE542K2.75
M71raltitrexed and oxaliplatin, raltitrexed and irinotecanCetuximab and irinotecanSD16.0G13DWT2.8
F53FOLFOX, FOLFIRI, irinotecanCetuximab and irinotecanSD20.0G12AWT2.25
F73FOLFOXCetuximab and irinotecanSD20.0WTWT2.25
M78FOLFOX, FOLFIRICetuximab and irinotecanPDWTWT2.4
F51FOLFIRI, FOLFOXCetuximab and irinotecanPDG12DWT3.2
F75FOLFIRI, oxaliplatin and capecitabineCetuximab and irinotecanPDG12VE542K2.3
M69LV5FU2 and oxaliplatin and irinotecan, FOLFIRICetuximab and irinotecanPDG13DWT3.3
M72LV5FU2, FOLFOX, FOLFIRI IV and oxaliplatin IAHCetuximab and irinotecanPDWTWT3.8
F61LV5FU2 and oxaliplatin and irinotecan, irinotecanCetuximab and irinotecanPDWTWT2.3
M53FOLFOX, FOLFIRI, raltitrexed and oxaliplatin, capecitabine, irinotecanCetuximab and irinotecanPDG12DWT2.3
M59FOLFIRI, FOLFOXCetuximab and irinotecanPDG12DWT2.9
M75FOLFOX, FOLFIRICetuximab and irinotecanPDG12DWT2.7
F58FOLFOX, FOLFIRI, LV5FU2 and mitomycin, FOLFOX, phase I trialCetuximab and irinotecanPDG12CWT3.7
M47LV5FU2, FOLFOX, FOLFIRICetuximab and irinotecanPDWTWT3.3
M41capecitabine and oxaliplatinCetuximab and irinotecanPDG12CWT3.6
F60FOLFIRI, FOLFOX, irinotecanCetuximab and irinotecanPDG13DWT2.7
  • Abbreviations: M, male; F, female; IAH, intra-artery hepatic infusion; IV, i.v. infusion; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NA, not applicable; FOLFOX, oxaliplatin, fluorouracil, and folinic acid; FOLFIRI, irinotecan, fluorouracil, and folinic acid; WT, wild type.

  • * Gene copy number per nucleus.